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Summary
A role for complement, particularly the classical pathway, in the regula-
tion of immune responses is well documented. Deficiencies in C1q or C4
predispose to autoimmunity, while deficiency in C3 affects the suppres-
sion of contact sensitization and generation of oral tolerance. Comple-
ment components including C3 have been shown to be required for both
B-cell and T-cell priming. The mechanisms whereby complement can
mediate these diverse regulatory effects are poorly understood. Our previ-
ous work, using the mouse minor histocompatibility (HY) model of skin
graft rejection, showed that both C1q and C3 were required for the induc-
tion of tolerance following intranasal peptide administration. By compar-
ing tolerance induction in wild-type C57BL/6 and C1q-, C3-, C4- and
C5-deficient C57BL/6 female mice, we show here that the classical path-
way components including C3 are required for tolerance induction,
whereas C5 plays no role. C3-deficient mice failed to generate a functional
regulatory T (Treg) –dendritic cell (DC) tolerogenic loop required for tol-
erance induction. This was related to the inability of C3-deficient DC to
up-regulate the arginine-consuming enzyme, inducible nitric oxide syn-
thase (Nos-2), in the presence of antigen-specific Treg cells and peptide,
leading to reduced Treg cell generation. Our findings demonstrate that
the classical pathway and C3 play a critical role in the peptide-mediated
induction of tolerance to HY by modulating DC function.
Keywords: complement; dendritic cells; regulatory T cells; rodent; toler-
ance.
Introduction
The complement system, a major component of innate
immunity, also has an important regulatory role in adap-
tive immune responses, where it is involved in both the
induction and control of B-cell and T-cell activation.1,2
A role for the classical pathway in immune regulation
stems from the observations that, in humans, deficiencies
in C1q or C4 predispose to systemic lupus erythemato-
sus.3 The absence of these components causes impaired
clearance of apoptotic cells4 and defective B-cell regula-
tion.5,6 C3 has also been reported to be important in the
regulation of immune responses, particularly in the
suppression of contact sensitization and generation of
oral tolerance,7–9 and has been recently demonstrated to
have an immunosuppressive role in the differentiation of
myeloid suppressor cells.10 Conversely, complement, par-
ticularly C3, is required for optimal B-cell immunity11–13
and T-cell priming.2,14,15 Signalling by the complement
fragments C3a and C5a through their receptors, C3aR
and C5aR, has been implicated in T-cell activation
directly16,17 or indirectly through dendritic cell (DC) acti-
vation.18–20 The mechanisms dictating the modulatory
function of complement in adaptive immunity remain
poorly understood and depend on the experimental con-
ditions applied.
Abbreviations: BMDC, bone-marrow-derived dendritic cells; B6, C57BL/6; CFSE, carboxyfluorescein diacetatesuccinimidyl ester;
DC, dendritic cells; Foxp3, Forkhead box p3; i.n., intranasal; iTreg, induced regulatory T; MST, median survival time; iNOS,
nitric oxide-synthase-2; TGF-b, transforming growth factor-b; Treg, regulatory T; WT, wild-type
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Similarly the role of complement in tolerance remains
unresolved. Although there is evidence that C3 is needed
for the rejection of fully MHC mis-matched kidney
grafts,21 we and others have found, using the minor his-
tocompatibility (HY) model of skin graft rejection, that
C1q and C3 were required not for rejection, but for the
induction of tolerance.22,23 We previously showed that
intranasally (i.n.) administered MHC class II-restricted
HY-AbDby peptide led to its presentation by immature
DC and the generation of peptide-specific CD4 regulatory
T (Treg) cells.24,25 Following skin grafting, or immuniza-
tion with male cells, the effect of these Treg cells was to
impair the presentation of the full cohort of MHC class I
and II male epitopes resulting in a diminished cytotoxic
T lymphocyte response and graft tolerance.24 These find-
ings were consistent with the notion of a regulatory feed-
back loop between Treg cells and DC and generation of a
population of tolerogenic DC.26,27
Here, we have extended our observations and uncov-
ered some potential mechanisms by which C3 might reg-
ulate the induction of peptide-induced tolerance and
linked suppression.
Materials and methods
Mice
C57BL/6 (B6) were from Harlan (Bicester, UK). B6.C1qa–/
–,28 B6.C3–/–,29 B6.C4–/–29 and B6.C5–/–30 were previously
described and backcrossed onto C57BL/6 for 10 genera-
tions. Mice with T-cell receptors transgenic for the
HY-AbDby peptide (Marilyn mice)31 were provided by Dr
O. Lantz (Paris, France). All experiments on animals com-
plied with standard conditions and were covered by a UK
Home Office Project License.
Tolerance induction and skin grafting
The HY-AbDby peptide (100 lg diluted in 20 ll PBS)
(NAGFNSNRANSSRSS; ThinkPeptides, Sarasota, FL) was
administered i.n. on 3 consecutive days to female mice
anaesthetized under isoflurane. Control mice received
PBS. Ten days later, skin grafting was performed32 using
male and female tail skin grafted onto the lateral thorax
of syngeneic female recipients. Grafts were scored as
rejected when < 10% viable tissue remained. After
100 days, selected mice were injected intraperitoneally
with 5 9 106 male splenocytes and 7 days later the
HY-specific CD8 T-cell response was measured using HY-
DbUty dextramer (Immudex, Copenhagen, Denmark).
Isolation of splenic DC and T-cell proliferation
Splenic DC were isolated using a CD11c-positive selection
kit (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Then, 25 9 104 CD4+ Marilyn T cells were added to puri-
fied DC and incubated for 72 hr. Wells were pulsed with
05 lCi [3H]thymidine for the last 18 hr. Plates were
counted using a Wallac Trilux 1450 MicroBeta liquid scin-
tillation counter (PerkinElmer LAS, Seer Green, UK).
Adoptive cell transfer
Marilyn CD4+ CD25 T cells were isolated from Marilyn
mice using a CD4 negative selection kit (Miltenyi Biotec
GmbH), followed by a CD25 selection kit (Miltenyi). Cells
were labelled with 5 lM carboxyfluorescein diacetatesuccin-
imidyl ester (CFSE; Molecular Probes, Life Technologies,
Paisley, UK) according to the manufacturer’s instructions.
Then 2 9 106 to 5 9 106 labelled cells were injected intra-
venously into each recipient. Results are shown as prolifera-
tion index, calculated using FLOWJO software.
Flow cytometry
Cells were stained using standard protocols in the pres-
ence of saturating anti-FccRII/III (2.4G2). The following
antibodies were used: anti-mouse CD90.1 (OX.7), anti-
mouse CD25 (PC61), anti-mouse CD4 (GK1.5), anti-
mouse CD40 (3/23), anti-mouse CD86 (GL1), anti-mouse
H-2A (2G9) from BD Biosciences (San Diego, CA); anti-
rat/mouse forkhead box p3 (Foxp3; FJK-16s), anti-mouse
CD8 (53–6.7) from Life Technologies. Data were acquired
using a FACSVERSE (Becton-Dickinson, Mountain View,
CA) and analysed using FLOWJO software, (TreeStar, Ash-
land, OR). Foxp3 staining was performed according to
the manufacturer (eBioscience, San Diego, CA).
Treg cell generation and suppression assay
CD4+ cells were isolated by negative selection (Miltenyi Bio-
tec GmbH) and cultured in RPM1-1640 at 106 cells/ml in
U-bottom wells coated with anti-CD3 antibody (1 lg/ml,
1452C11, Biolegend, San Diego, CA) and anti-CD28 anti-
body (1 lg/ml; eBioscience); in the presence of recombi-
nant human transforming growth factor-b (TGF-b; 10 ng/
ml, PeproTech, Rocky Hill, NJ), anti-interferon-c antibody
(25 lg/ml, Biolegend) and r-mouse interleukin-2 (5 ng/
ml) for 4 days. The T-cell suppression assay was performed
as previously described.33 Proliferation was expressed as a
division index, calculated using FLOWJO software.
Co-culture assays
Bone marrow dendritic cells (BMDC) were generated as
previously described.34 Marilyn induced Treg (iTreg) cells
were obtained from naive Rag2–/– Marilyn spleen cells
(5 9 105 cells/ml) cultured with BMDC (105 cells/ml),
HY-AbDby peptide (10 nM), recombinant human TGF-b
(2 ng/ml) and retinoic acid (1 lM, Sigma, St Louis, MO)
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for 5 days. Live cells were recovered on a gradient density
(Lympholyte, Cedarlane Laboratories, Burlington, ON,
Canada). Staining indicated ≥ 70% Foxp-3+ cells. Fresh
BMDC (106 cells/ml) were co-cultured with iTreg cells
(106 cells/ml) in the presence or absence of HY-AbDby
peptide (1 nM) for 48 hr.
Quantitative real-time RT-PCR
RNA was extracted from cell cultures using RNeasy col-
umns (Qiagen, Hilden, Germany). The cDNA was gener-
ated using an iScript cDNA synthesis Kit (BioRad,
Hercules, CA). Real-time PCR were performed using spe-
cific primers (see Supporting information, Table S1) with
SYBR green master mix (Applied Biosystems, Life Tech-
nologies, Paisley, UK) and analysed on a ViiATM7 RealTime
PCR system (Applied Biosystem, Life Technologies). Rel-
ative quantities were calculated using the DDCt method.35
Samples that gave no detectable signal were attributed a Ct
value of 40; samples were normalized to Gapdh.
Statistical analysis
Comparisons between two groups were performed using
two-tailed unpaired Student’s t-test. Graft survival was
compared using the log-rank test. Statistical significance
is defined as P ≤ 005.
Results
Early components of the classical pathway are
required for induction of nasal tolerance
C57BL/6 (B6) wild-type (WT) female mice can be toler-
ized to the male HY antigen by i.n. administration of the
HY-AbDby peptide,25 but not in the absence of C1q or
C3.22 To establish whether the terminal pathway of com-
plement was also required, C5-deficient (B6.C5–/–) female
mice received i.n. HY-AbDby peptide and 10 days later
were grafted with male skin. Peptide-treated B6.C5–/–
females became tolerant, maintaining the male graft as
well as WT mice (Fig. 1a). In contrast, as previously
reported,22 female mice lacking C1q (B6.C1qa–/–) or C3
(B6.C3–/–) started to lose their grafts with median survival
times (MST) of 34 and 37 days, respectively and fewer
than 20% retained their graft after 100 days. Syngeneic
female grafts were accepted indefinitely. As both C1q36,37
and C37–10 have been shown to independently regulate
immune responses, we performed similar experiments
with C4-deficient female mice (B6.C4–/–) to investigate
whether the early components of the classical pathway
were required for tolerance induction. No long-term toler-
ance was achieved in these mice; they rejected their grafts
with an MST of 47 days, which was not statistically differ-
ent from that of B6.C1qa–/– and B6.C3–/– mice (Fig. 1a).
Moreover, these graft survival times were not different
from that of non-peptide treated WT mice (MST
31 days). These results therefore indicate a role for the
early phase of the classical pathway of complement activa-
tion, rather than an independent role for the individual
components C1q and C3 or the terminal pathway. To fur-
ther confirm these findings, some mice were given an in
vivo boost with male cells 100 days after grafting and their
CD8 T-cell response was measured 7 days later using an
HY-peptide-specific (HY-DbUty) dextramer (Fig. 1b). The
tolerant WT and B6.C5–/– mice gave a very low anti-HY-
specific CD8 T-cell response, whereas the non-tolerant
C3-deficient and C4-deficient mice showed large expan-
sions of the HY-DbUty dextramer+ CD8 T-cell population,
indicating a failure in the non-tolerant animals to control
the cytotoxic response against HY. Hence, the early phase
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Figure 1. Impaired induction of tolerance in mice lacking early
components of the classical complement pathway. B6 wild-type
(WT; black circle), B6.C1qa–/–- (grey triangles), B6.C4–/– (grey
squares), B6.C3–/– (black triangles) and B6.C5–/– (grey diamonds)
female mice were given HY-AbDby peptide (100 lg for 3 days) intra-
nasally. (a) Survival of syngeneic male skin grafts transplanted on
peptide-treated female WT (n = 11), B6.C1qa–/– [n = 5, median sur-
vival time (MST) 34 days, P = 00141], B6.C4–/– (n = 7, MST
47 days, P = 00045), B6.C3–/– (n = 7, MST 33 days, P = 00030),
B6.C5–/– (n = 10, P = 06039). Syngeneic female grafts were accepted
indefinitely. Statistical analysis was performed using the log-rank
method comparing separately each complement-deficient strain to
peptide-treated WT B6. (b) 100 days after skin grafting, selected
mice were injected intraperitoneally with 5 9 106 male splenocytes
and 7 days later spleen cell suspensions were analysed for HY-spe-
cific CD8 T-cell responses (HY-DbUty dextramer+ CD8 T cells) by
flow cytometry. B6 (n = 9), B6.C5–/– (n = 7), B6.C4–/– (n = 4),
B6.C3–/– (n = 4). Statistical analysis: t-test.
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of the classical pathway plays a key role in this model of
tolerance. As C3 is central to this, we elected to focus on
this molecule to investigate possible mechanisms.
C3 does not affect peptide dissemination in vivo
The initial phase in this model of tolerance induction is
the presentation of the peptide by antigen-presenting
cells, most likely DC. Twenty-four hours after the i.n.
administration the peptide is found in CD11c-positive
DC in spleen, and in peripheral and cervical draining
lymph nodes.24 To determine whether complement
affected the peptide dissemination and/or presentation,
B6 WT and B6.C3–/– female mice were given i.n. HY-
AbDby peptide. Twenty-four hours later splenic DC were
isolated and used to stimulate HY-AbDby-specific CD4+ T
cells from TCR transgenic Marilyn mice (Marilyn T cells).
The purity, percentage of CD8+/CD8 DC and expression
levels of CD40, CD86 and H2-Ab were similar (data not
shown). Regardless of their complement status splenic,
DC from the peptide-treated mice were equally able to
stimulate the proliferation of the Marilyn T cells (Fig. 2);
hence complement does not influence the distribution or
initial presentation of the peptide.
The early phase of tolerance induction is defective in
B6.C3–/– mice
To study the early phase of tolerance induction, concomi-
tantly with i.n. peptide administration, we adoptively
transferred intravenously CFSE-labelled Marilyn CD4 T
cells to act as indicators of the endogenous anti-HY
response. This protocol has been previously shown to
have no effect on peptide-mediated tolerance induction.24
Proliferation was assessed at days 4, 5 and 6 (Fig. 3a).
No differences in proliferation were observed at day 4,
confirming that complement does not play a role in the
early distribution and presentation of the peptide. By day
5 Marilyn T cells transferred into B6.C3–/– mice had
divided extensively, and by day 6 most of the cells were
CFSE negative. In contrast, Marilyn T cells transferred
into WT mice demonstrated a significantly slower rate of
proliferation (Fig. 3b,c).
To determine whether complement affected Treg cell
induction in the adoptively transferred Marilyn T cells, we
examined Foxp3 expression at days 4 and 6 (Fig. 3d). At
day 4 the mean fluorescence intensity of Foxp3 in the Mari-
lyn T cells was increased compared with the PBS-treated
controls,38 irrespective of the complement status of the
recipient mice (Fig. 3d, left hand panel). The percentage of
Foxp3+ Marilyn T cells was similar. By day 6, the percent-
age of Foxp3+ Marilyn T cells had increased in the peptide-
treated compared with the PBS-treated mice, again regard-
less of the complement status of the hosts (Fig. 3d, right
hand panel). Hence, although C3 was required for the pep-
tide-mediated regulation of proliferation of the adoptively
transferred Marilyn T cells, it appeared to have little effect
on the induction of Foxp3+ Treg cells.
The early phase of the induction of linked tolerance
is impaired in B6.C3–/– mice
To examine the early phase of induction of linked tolerance,
to the additional HY epitopes expressed on male tissue, B6
WT and B6.C3–/– mice were given an intraperitoneal injec-
tion of male splenocytes 10 days after receiving three doses
of HYAbDby peptide or control PBS. At the same time,
CFSE-labelled Marilyn T cells were injected intravenously
(Fig. 4a). At day 3 there was minimal proliferation by the
Marilyn T cells, even from the peptide-treated mice. How-
ever, by days 5 and 6 a marked increase in the proliferation
of Marilyn T cells in response to the immunization with
male cells was found in the control PBS-treated mice
regardless of their complement status as well as in the pep-
tide-treated B6.C3–/– mice. In contrast, there was signifi-
cantly less proliferation in the peptide-treated WT mice
compared with the PBS-treated controls. (Fig. 4b).
Endogenous Treg cells are expanded in peptide-treated
mice following immunization with male antigen.24,39 We
therefore examined the percentage of Foxp3+ cells within
the adoptively transferred Marilyn T-cell population fol-
lowing encounter with male antigen. At day 3 there was
no expansion of Foxp3+ cells. However, by days 5 and 6
the percentage of Foxp3+ Marilyn T cells was increased in
the peptide-treated WT mice compared with PBS-treated
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controls, whereas in B6.C3–/– mice no such induction was
observed (Fig. 4c).
We also examined expansion of endogenous HY-spe-
cific CD8 effector T cells. On day 5 there was no expan-
sion of HY-specific CD8 T cells within the CD8
population from either peptide-treated WT or B6.C3–/–
mice. However, by day 6 we observed expansions that
were significantly greater in the B6.C3–/– compared with
WT animals (Fig. 4d).
Taken together, these findings indicate that in C3-defi-
cient mice the generation of Treg cells is impaired, perhaps
because of a defect in the induction of the tolerogenic loop.
Consistent with this, both the adoptively transferred Mari-
lyn T cells and the endogenous HY-specific CD8 T cells
divided more extensively in the peptide-treated C3-defi-
cient mice than in the corresponding WT controls.
C3 deficiency in T cells does not affect their capacity
to become Treg cells
Administration of the peptide to B6.C3–/– mice resulted
in a defective induction of Treg cells within the
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adoptively transferred C3-sufficient Marilyn T cells
(Fig. 4c). However, it was not possible to evaluate the
endogenous HY-peptide specific C3-deficient Treg cells
in vivo or ex vivo. Therefore we assessed whether C3 defi-
ciency could affect the in vitro induction of Treg cells from
naive CD4 T cells. Using a standard protocol40 we found
that the generation of iTreg cells from WT and B6.C3–/–
mice was similar (see Supporting information, Fig. S1A).
In addition, both iTreg populations were functionally
equivalent in suppression assays, irrespective of whether
the responder T cells were WT (see Supporting informa-
tion, Fig. S1B) or C3-deficient (Fig. S1C). These results
suggest that there is no inherent inability in the B6.C3–/– T
cells to become Treg cells.
Induction of tolerogenic DC appears to be impaired
in C3-deficient mice
Although it is well established that DC make up a central
component of the tolerance-inducing pathway, the identifi-
cation and characterization of these cells in vivo have pro-
ven to be difficult. It has recently been reported that the
generation of Treg cells from naive T cells, a process known
as infectious tolerance, was a result of the induction of
amino-acid-metabolizing enzymes in the antigen-presenting
DC. In addition, culture of in-vitro-generated Treg cells
with BMDC in the presence of cognate peptide induced a
similar set of amino-acid-consuming enzymes, arginase 1
(Arg-1), nitric oxide synthase 2 (Nos-2), interleukin-4-
induced 1 (Il4i-1) and indolamine 2,3-dioxygenase (Indo-1)
in the DC.41 Using a similar approach, we cultured WT
and B6.C3–/– BMDC with Foxp3+ Marilyn iTreg cells. This
induced C3 expression (see Supporting information, Fig.
S2) and an increase in Nos-2 transcription in the WT DC
compared with DC alone. Transcription was further
increased in the presence of cognate peptide (Fig. 5). When
C3-deficient DC were used, the expression of the Nos-2
gene in the presence of peptide was significantly lower
(Fig. 5). Arg-1 expression was up-regulated following incu-
bation of the DC with Marilyn iTreg cells, but the presence
of the cognate peptide did not further increase its expres-
sion, as was reported previously.41 However, there was no
significant difference in expression of Arg-1 between the
WT and C3-deficient DC. We found no obvious differences
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Figure 4. Induction of antigen-specific regula-
tory T (Treg) cells in peptide-treated mice after
immunization with male cells. Ten days after
intranasal (i.n.) treatment with three doses of
peptide (100 lg), female B6 wild-type (WT) or
B6.C3–/– mice (three or four animals per
group) were challenged intraperitoneally with
5 9 106 male splenocytes. The antigen-specific
CD4 T-cell response was monitored by infus-
ing 2 9 106 CFSE-labelled Marilyn CD90.1
CD4+ CD25 T cells intravenously. Three, 5
and 6 days after the challenge, splenocytes were
recovered and the proliferation of Marilyn T
cells (gated as CD4+ CD90.1+) was analysed by
flow cytometry (a) Experimental schedule. (b)
Proliferation indices of Marilyn T cells. (c)
Percentage of Foxp3+ Marilyn T cells. Results
from mice treated with PBS (open column)
and peptide (filled column) are shown. Bars
indicate SEM; P-values of unpaired t-test are
indicated. (d) Five and 6 days after the chal-
lenge, splenocytes were recovered and analysed
for HY-specific CD8 T-cell responses (HY-
DbUty dextramer+ CD8 T cells) by flow
cytometry. Bars indicate SEM. P-values of
unpaired t-test are indicated.
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in the expression of IL-4i or Indo-1 in the co-culture of DC
and Marilyn iTreg cells with or without peptide compared
with DC alone. Again the absence of C3 did not alter the
expression of these genes.
Discussion
The role of complement in the regulation of immune
responses remains controversial. Here we have extended
our previous studies and show that, in addition to C1q
and C3, C4 is also needed for peptide-induced tolerance,
confirming the key role of the early components of the
classical pathway. The finding that B6.C5–/– mice can be
tolerized as well as WT demonstrates that the terminal
pathway is not involved.
We and others have shown that this model of peptide-
induced tolerance involves the induction of a dominant
regulatory mechanism mediated by Foxp3+ CD4 Treg
cells and resulting in impaired expansions of HY-specific
CD4 and CD8 T cells.24,25,39 The lack of tolerance in
C3-deficient mice was accompanied by increased prolifer-
ation of the adoptively transferred HY-specific CD4 T
cells and expansion of endogenous HY-specific CD8 T
cells. This correlated with a lower frequency of Foxp3+
CD4 Treg cells within the adoptively transferred indicator
Marilyn T cells. Collectively, these results suggest that the
generation of Treg cells and the subsequent Treg–DC
tolerogenic loop26,27 was defective in the absence of C3.
Using naive CD4 T cells we were unable to demonstrate a
role for C3 in the induction of Treg cells in vitro. More-
over, the cells from both WT and B6.C3–/– animals were
equally suppressive, demonstrating that in the presence of
exogenous TGF-b, there is no intrinsic defect in the abil-
ity of B6.C3–/– T cells to differentiate into functional
Foxp3+ Treg cells. Our observations that there were fewer
Foxp3+ Marilyn T cells, which are complement-sufficient,
following adoptive transfer into peptide-treated B6.C3–/–
recipients immunized with male cells, pointed to a defect
within the DC rather than the T-cell populations.
How does the classical pathway of complement affect
tolerance induction? It has recently been shown that all
the subcomponents of the C1 complex (C1q, C1r, C1s)
are not only synthesized by, but are also present on the
surface of human monocytes,42 supporting the idea of
local complement activation via the classical pathway on
the surface on monocytes and possibly other bone-mar-
row-derived cells. Although we found that both C1q and
C4 were needed for tolerance induction, C3 deficiency
gave the same phenotype, indicating that C3, with its
associated regulatory function7–9 may play a central role
in mediating tolerance in this model. Following the cog-
nate interaction between DC and CD4 T cells, both cell
types can produce C3, although T cells to a far less extent
(17 and see Supporting information, Fig. S2). A possible
scenario would therefore be that local production of com-
plement causing the activation of C3 would lead to the
generation of C3 activation fragments, C3a and C3b.
Despite evidence suggesting that C3a and C5a signalling
through their respective C3aR and C5aR receptors is
important for T-cell activation16,17,19,20 and that this sig-
nalling leads to suppression of Treg cell generation,43 our
results and those of others23 clearly show that C3 is
required for tolerance induction. Our observation that C5
deficiency did not affect peptide-induced tolerance also
argues against a role for C5aR signalling. In addition, the
C3-deficient mice used in our study cannot generate any
intracellular C3a fragment as they lack the corresponding
genetic region,29 making it unlikely that the effects we
observed were mediated by intracellular or extracellular
C3aR. Nonetheless, the possibility of a C3-mediated intra-
cellular signalling mediated by other C3 fragments cannot
be excluded.44
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Figure 5. Induction of amino acid-consuming enzymes in dendritic cells (DC) by inducible regulatory T (iTreg) cells. Bone-marrow-derived den-
dritic cells (BMDC) from B6 wild-type (WT; closed symbols) or B6.C3–/– mice (open symbols) were cultured either alone or with induced Mari-
lyn Treg cells (ratio 1 : 1), in the absence or in the presence of 1 nM HY-AbDby peptide for 48 hr. Samples were analysed for gene expression by
real-time PCR using specific primers for Nos-2, Arg-1, IL4i-1 and Indo-1. Relative expression was normalized to Gapdh. Data are represented as
relative quantification (RQ); each dot represents a separate biological replicate (seven per group). P-values are indicated (t-test).
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 144, 149–157 155
Complement and tolerance induction
We have previously shown that following i.n. peptide
administration, a population of Treg cells with up-regu-
lated expression of Foxp3, CTLA4, programmed cell
death 1 and lymphocyte activation gene 3 as well as inter-
feron-c and interleukin-1324 was generated. Expression of
these molecules causes down-modulation of DC matura-
tion and co-stimulatory capacity45,46 and the induction of
the amino acid catabolizing enzymes indolamine 2,3-di-
oxygenase47,48 and Arginase 1.49 This gives rise to tolero-
genic DC, which in turn interact with naive CD4 T cells
recognizing cognate MHC peptide and causing down-reg-
ulation of the T-cell mammalian target of rapamycin
(mTOR) signalling pathway, up-regulation of Foxp3 and
further Treg cell generation.50,51 Hence establishing a tol-
erogenic loop.26,27
Related to this, here we have identified a potential
explanation for the defective ability of the B6.C3–/– DC to
induce non-responsiveness: an impaired induction of
Nos2 expression following culture with in vitro-generated
HY-specific Treg cells in the presence of the cognate pep-
tide. Nos2 encodes inducible nitric oxide synthase 2
(iNOS), an enzyme shown to have an important role in
the reduction of available arginine, which is crucial for
the induction of infectious tolerance through the mTOR
signalling pathway.41,50 Although NO generation by iNOS
has been associated with pro-inflammatory responses,
there is now good evidence that NO has direct immuno-
regulatory effects.52,53 Given the importance of iNOS in
immune regulation, it is plausible that C3 contributes to
tolerance induction in the intranasal peptide model by
modulating its expression.
In summary, our results have shown that the comple-
ment classical pathway, and particularly C3, is important
for the induction of tolerance to HY by the intranasal
administration of a single MHC class II-restricted HY
peptide. The defect is likely to be related to the inability
of complement-deficient mice to establish the Treg–DC
tolerogenic loop required for the induction and mainte-
nance of tolerance. We found no evidence of a defect in
the ability of C3-deficient T cells to generate Treg cells
using established in vitro protocols arguing against an
intrinsic T-cell defect. Rather the finding that B6.C3–/–
BMDC produced significantly less iNOS following incu-
bation with T cells and cognate antigen, suggests that the
defect is at the level of the antigen-presenting cells. In the
absence of C3, the induction of amino-acid-depleting
enzymes in DC is impaired, causing reduced Treg cell
generation, possibly as a result of impaired down-regula-
tion of the mTOR pathway.
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